Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation

Journal of the American College of Cardiology

Volumn 38, Issue 7, 2001, Pages 2006-2012

  Walter, Dirk H ^a   Fichtlscherer, Stephan ^a   Britten, Martina B ^a   Rosin, Patrick ^a   Auch Schwelk, Wolfgang ^a   Schächinger, Volker ^a   Zeiher, Andreas M ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CERIVASTATIN; CLOPIDOGREL; FLUINDOSTATIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; STATIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; DISEASE COURSE; DRUG SAFETY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESTENOSIS; RISK ASSESSMENT;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICHOLESTEREMIC AGENTS; C-REACTIVE PROTEIN; COMBINED MODALITY THERAPY; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; CORONARY RESTENOSIS; CORONARY STENOSIS; FEMALE; FOLLOW-UP STUDIES; GRAFT OCCLUSION, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; RETREATMENT; STENTS;

EID: 0035195541     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(01)01662-X     Document Type: Article

References (28)

1. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction
2. Production of C-reactive protein and risk of coronary events in stable and unstable angina
3. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina
4. Predictive value of C-reactive protein and troponin T in patients with unstable angina: A comparative analysis. CAPTURE investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial
5. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
6. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty
7. Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina
8. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation
9. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol And Recurrent Events (CARE) investigators
10. Novel inflammatory markers of coronary risk: Theory versus practice
11. Stafin trials and goals of cholesterol-lowering therapy
12. Current perspectives on statins
13. Effect of statin therapy on restenosis after coronarv stent implantation
14. Adjunctive intracoronary infusion of antithrombin III during percutaneous transluminal coronary angioplasty. Results of a prospective, randomized trial
15. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
16. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
17. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
18. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial
19. Neointimal tissue response at sites of coronary stenting in humans: Macroscopic, histological, and immunohistochemical analyses
20. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina
21. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease
22. Association of heparin-resistant thrombin activity with acute ischemic complications of coronary interventions
23. Late lumen loss after coronary angioplasty is associated with the activation status of circulating phagocytes before treatment
24. Procoagulant inflammatory responses of monocytes after direct balloon angioplasty in acute myocardial infarction
25. Serum levels of circulating adhesion molecules after coronary angioplasty
26. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis
27. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) trial
28. Hyperlipidemia and coronary diseas. Correction of the increased thrombogenic potential with cholesterol reduction